+41 91 682 20 40 info@elixi-int.com

Teva Announces the Launch of a Generic Version of Lialda (mesalamine) in the United States

On  Mar. 26, 2018,  Teva Pharmaceutical Industries Ltd has announced the launch of a generic version of Lialda (mesalamine) delayed-release tablets, 1.2 g, in the U.S.

Mesalamine delayed-release tablets are indicated for the induction of remission in adults with active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis.

“The launch of mesalamine is a significant addition to Teva’s generic portfolio,” said Brendan O’Grady, Executive Vice President and head of North America Commercial at Teva. “With more than a million people in the U.S. estimated to suffer from inflammatory bowel diseases, including ulcerative colitis, this is an important and more affordable generic treatment option for our customers.”

 

Mesalamine delayed-release tablets are indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis.

Mesalamine delayed-release tablets are contraindicated in patients with known hypersensitivity to salicylates or aminosalicylates or to any of the ingredients of mesalamine delayed-release tablets.

Renal Impairment, including minimal change nephropathy, acute and chronic interstitial nephritis, and, rarely, renal failure, has been reported in patients given products that contain mesalamine or are converted to mesalamine. Mesalamine has been associated with an acute intolerance syndrome that may be difficult to distinguish from an exacerbation of ulcerative colitis.

Some patients who have experienced a hypersensitivity reaction to sulfasalazine may have a similar reaction to compounds that contain or are converted to mesalamine. Mesalamine-induced cardiac hypersensitivity reactions (myocarditis and pericarditis) have been reported with mesalamine delayed-release tablets and other mesalamine medications. There have been reports of hepatic failure in patients with pre-existing liver disease who have been administered mesalamine.

Pyloric stenosis or other organic or functional obstruction in the upper gastrointestinal tract may cause prolonged gastric retention of mesalamine which would delay mesalamine release in the colon. The most common adverse reactions (incidence greater than or equal to 2 %) in clinical trials were ulcerative colitis, headache, flatulence, liver function test abnormality, and abdominal pain.

For more information and fast delivery of the life-saving, latest FDA approved oncology drugs, please contact us at info@elixi-int.com

We are a Swiss pharmaceutical wholesaler, specialised in sourcing and delivering pharma products, medical devices and drugs from and to all over the world.